Efficacy and safety of rosuvastatin
Pro Research Analysisby 
Searched over 200M research papers
Rosuvastatin Efficacy in Lowering LDL Cholesterol and Improving Lipid Profiles
Rosuvastatin is highly effective at lowering low-density lipoprotein (LDL) cholesterol, with reductions ranging from 39% to 63% depending on the dose, which is greater than reductions seen with other statins like atorvastatin, simvastatin, and pravastatin Mckenney2005Brown2002. In both adults and children with familial hypercholesterolemia, rosuvastatin significantly lowers LDL cholesterol, with a 50% reduction observed at the 20 mg dose in children . In real-world clinical practice, rosuvastatin also leads to significant improvements in total cholesterol, LDL cholesterol, and triglyceride levels, contributing to reduced cardiovascular risk . Studies in East Asian populations confirm that both generic and proprietary formulations of rosuvastatin are equally effective in lowering LDL cholesterol, with target achievement rates around 75% to 77% .
Comparative Efficacy: Rosuvastatin vs. Other Statins and Combination Therapies
When compared to pravastatin and simvastatin, rosuvastatin achieves greater LDL cholesterol reductions and enables more patients to reach their cholesterol goals . In patients with coronary artery disease, rosuvastatin and atorvastatin show similar efficacy for major cardiovascular outcomes over three years, but rosuvastatin achieves lower average LDL cholesterol levels . In the context of cerebral infarction, both loading-dose atorvastatin and rosuvastatin improve clinical outcomes, but rosuvastatin provides superior lipid control . Additionally, combining moderate-intensity rosuvastatin with ezetimibe is more effective at improving lipid profiles than high-intensity rosuvastatin alone in high-risk patients with type 2 diabetes .
Efficacy in Special Populations: Children, Metabolic Syndrome, and Hypertension
In children with familial hypercholesterolemia, rosuvastatin is effective in reducing LDL cholesterol, though only 40% reach the strictest LDL targets due to high baseline levels . For patients with metabolic syndrome and moderate to severe metabolic associated fatty liver disease (MAFLD), rosuvastatin significantly reduces liver fat and improves lipid metabolism without compromising safety . In patients with both hypertension and hyperlipidemia, rosuvastatin—alone or combined with nebivolol—effectively lowers LDL cholesterol and blood pressure, with high rates of target achievement and a favorable safety profile .
Safety Profile of Rosuvastatin
Rosuvastatin is generally well tolerated, with a safety profile similar to other statins regarding muscle, liver, and kidney toxicity Mckenney2005Brown2002Kim2024+1 MORE. Large-scale observational studies report low rates of adverse events (about 1.6%), and no significant cases of statin-associated myopathy, hepatotoxicity, or diabetes were observed . In comparative studies, the incidence of adverse reactions is similar between rosuvastatin and other statins, and between generic and proprietary formulations Kim2020Li2024. However, in long-term use among coronary artery disease patients, rosuvastatin is associated with a higher risk of new-onset diabetes and cataract surgery compared to atorvastatin, though other safety outcomes are similar .
Conclusion
Rosuvastatin is a potent and effective statin for lowering LDL cholesterol and improving overall lipid profiles in a variety of populations, including adults, children, and those with comorbid conditions. Its safety profile is comparable to other statins, with low rates of adverse events in both clinical trials and real-world practice. While it may carry a slightly higher risk of new-onset diabetes and cataract surgery compared to atorvastatin, its overall benefits in lipid management and cardiovascular risk reduction make it a valuable option for treating dyslipidemia and related conditions Mckenney2005Brown2002Avis2010+7 MORE.
Sources and full results
Most relevant research papers on this topic
Efficacy and safety of rosuvastatin in treatment of dyslipidemia.
Rosuvastatin effectively lowers LDL cholesterol and non-HDL-cholesterol levels, enabling more patients to reach their LDL cholesterol goals with an acceptable safety profile compared to other statins.
DOI